– Automatic conversion to be effective March 14, 2022 – NEW YORK, Feb. 23, 2022 /CNW/ — Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the “Company”), a clinical-stage biopharmaceutical company developing psychedelic-inspired therapies for the treatment of brain-based disorders, announced today that all the Company’s issued and outstanding multiple voting shares (the…

Source

Previous articleCOMPASS Pathways announces financial results for the fourth quarter and full year 2021 and business highlights
Next articlePharmaDrug Receives Positive Results for DMT-Analogue Program to Treat Glaucoma